ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
News
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform,...
Green Flash Launches New Beers Across the U.S. and Unveils Refreshed Branding
Year-Round Brews Bolster WEST COAST IPA® Lineup Green Flash Brewing Company's Year-Round Brews Featured: The brand’s iconic WEST COAST IPA®...
Walden Biosciences Announces Participation at October Investor Conferences
Presentations to highlight transformational, disease-modifying approach to treating kidney diseasesCAMBRIDGE, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc....
Skylight Health Announces Trading On OTCQX and DTC Eligibility
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SHG; OTCQX: SLHGF) (“Skylight Health” or the “Company”), a...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)...
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
• Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months • 80% of...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...
Teleflex Announces Third Quarter 2022 Earnings Conference Call Information
WAYNE, Pa., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third...
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy
SEATTLE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the...
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement...
Immuron strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately...
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,...
Philips expands rollout of its ClarifEye augmented reality surgical navigation solution to Japan
Philips’ augmented reality (AR) surgical navigation solution ClarifEye Philips ClarifEye live AR guidance Philips ClarifEye AR guidance Philips Azurion October...
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or...
IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana
New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A.,...
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Fagron delivers topline growth of 21.5% to €173 million
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2022 – 7.00 AM CET Fagron delivers topline growth of 21.5% to €173...
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative...
DICE Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...